BACKGROUND: The immunogenicity of the trivalent inactivated influenza split virus vaccine (Infusplit SSW 97/98) containing A/Bayern/07/95 (H1N1)-like (A/Johannesburg/82/96 [NIB-39]), A/Wuhan/359/95 (H3N2)-like (A/Nanchang/933/95 [Resvir-0]), and B/Beijing/184/93-like (B/Harbin/7/94) hemagglutinin antigens was tested in liver transplant recipients (TXL-R). SUBJECTS AND METHODS: Serum antibody titers were determined 21+/-2 days after a single vaccination in 62 adult TXL-R and 59 adult volunteers. RESULTS: Protective postimmunization antibody titers for the three antigens were similar in TXL-R (protection rates 92%, 92%, and 95%) and the comparison group (97%, 100%, and 100%). Adverse reactions were mild and less frequent in TXL-R. A significant decrease of CD8+CD38+ lymphocytes after vaccination was found in TXL-R. No association between antibody response and age, gender, time interval since transplantation, anti-hepatitis B surface antigen immunoprophylaxis, or immunosuppressive medication was detected. CONCLUSION: Our results show that the vaccine is safe and effective and should be recommended to TXL-R.
BACKGROUND: The immunogenicity of the trivalent inactivated influenza split virus vaccine (Infusplit SSW 97/98) containing A/Bayern/07/95 (H1N1)-like (A/Johannesburg/82/96 [NIB-39]), A/Wuhan/359/95 (H3N2)-like (A/Nanchang/933/95 [Resvir-0]), and B/Beijing/184/93-like (B/Harbin/7/94) hemagglutinin antigens was tested in liver transplant recipients (TXL-R). SUBJECTS AND METHODS: Serum antibody titers were determined 21+/-2 days after a single vaccination in 62 adult TXL-R and 59 adult volunteers. RESULTS: Protective postimmunization antibody titers for the three antigens were similar in TXL-R (protection rates 92%, 92%, and 95%) and the comparison group (97%, 100%, and 100%). Adverse reactions were mild and less frequent in TXL-R. A significant decrease of CD8+CD38+ lymphocytes after vaccination was found in TXL-R. No association between antibody response and age, gender, time interval since transplantation, anti-hepatitis B surface antigen immunoprophylaxis, or immunosuppressive medication was detected. CONCLUSION: Our results show that the vaccine is safe and effective and should be recommended to TXL-R.
Authors: Adriana Weinberg; Amanda A Allshouse; Samantha Mawhinney; Jennifer Canniff; Lorie Benning; Eryka L Wentz; Howard Minkoff; Mary Young; Marek Nowicki; Ruth Greenblatt; Mardge H Cohen; Elizabeth T Golub Journal: J Acquir Immune Defic Syndr Date: 2012-05-01 Impact factor: 3.731
Authors: James D Heffelfinger; Pragna Patel; John T Brooks; Helene Calvet; Charles L Daley; Hazel D Dean; Brian R Edlin; Kathleen F Gensheimer; John Jereb; Charlotte K Kent; Jeffrey L Lennox; Janice K Louie; Ruth Lynfield; Philip J Peters; Lauretta Pinckney; Philip Spradling; Andrew C Voetsch; Anthony Fiore Journal: Am J Public Health Date: 2009-10 Impact factor: 9.308
Authors: Charles R Beck; Bruce C McKenzie; Ahmed B Hashim; Rebecca C Harris; Arina Zanuzdana; Gabriel Agboado; Elizabeth Orton; Laura Béchard-Evans; Gemma Morgan; Charlotte Stevenson; Rachel Weston; Mitsuru Mukaigawara; Joanne Enstone; Glenda Augustine; Mobasher Butt; Sophie Kim; Richard Puleston; Girija Dabke; Robert Howard; Julie O'Boyle; Mary O'Brien; Lauren Ahyow; Helene Denness; Siobhan Farmer; Jose Figureroa; Paul Fisher; Felix Greaves; Munib Haroon; Sophie Haroon; Caroline Hird; Rachel Isba; David A Ishola; Marko Kerac; Vivienne Parish; Jonathan Roberts; Julia Rosser; Sarah Theaker; Dean Wallace; Neil Wigglesworth; Liz Lingard; Yana Vinogradova; Hiroshi Horiuchi; Javier Peñalver; Jonathan S Nguyen-Van-Tam Journal: PLoS One Date: 2011-12-22 Impact factor: 3.240